Novartis enters deal for Arvinas’ prostate cancer therapy

1 year ago 57

Novartis has signed an exclusive strategic licence agreement for Arvinas’ ARV-766, a new treatment for prostate cancer.

1. Homepage
2. Prostate Cancer
3. Novartis enters deal for Arvinas’ prostate cancer therapy